Familial Chylomicronemia Syndrome Pipeline
Nov 28, 2025
Arrowhead Hits the Mark in FCS Treatment with REDEMPLO Approval—Now Comes the Ionis Challenge
Arrowhead Pharmaceuticals has reached a transformational milestone with the FDA’s approval of REDEMPLO (plozasiran) on November 18, 2025—marking the company’s first FDA-approved medicine and the first-ever FDA-approved siRNA therapeutic for familial chylomicronemia syndrome (FCS) treatment. This historic approval r...
Read More...
Jul 24, 2020
Rejections and Withdrawals: Familial Chylomicronemia Syndrome Market Needs a Therapy sufficiently Effective, sufficiently Affordable
A rare autosomal recessive disorder, Familial chylomicronemia syndrome (FCS) affects 1 in 1 to 2 million people (Burnett and Hegele, 1999; Pouwels et al. 2008). As per DelveInsight, the total Familial chylomicronemia syndrome diagnosed prevalent population in the 7MM [the US, EU4 (Germany, Franc...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
